1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response - None of the above
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [sanjeeblama69@gmail.com].
   


6. For how long will this data be available start date provided 05-12-2025 and end date provided 05-12-0020?
   Response - Beginning 9 months and ending 36 months following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - Nil

In the first 6 months, 30 patients will be enrolled in the trial as a control group. They will be assessed for sepsis using the Sequential Organ Failure Assessment (SOFA) scoring tool. 

Baseline SOFA score will be assumed to be zero in patients not known to have any pre-existing organ dysfunction and those with a score of 2 or above will be considered to have sepsis and eligible for study. In patients with pre-existing organ dysfunction, there should be acute change in total SOFA score by ≥ 2 points consequent to infection to be eligible. A patient will be considered to have an infection if the treating physician stated infection in the medical record or started antibiotics or there are serological (immunoglobulin titres) and/or microbiological evidence (body fluids positive for microbes with staining techniques or cultures) of infection. Patient meeting the criteria for sepsis with persisting hypotension requiring vasopressors to maintain MAP≥ 65 mmHg and having a serum lactate level >2 mmol/l (18mg/dl) despite adequate fluid resuscitation will be considered to be in septic shock.

Those who meet the inclusion and exclusion criteria, will be included in the study. Participants in this group will receive conventional (standard) ICU care with standard sepsis management algorithms and will be monitored for 14 days in the ICU or until discharged, death, or transfer to general ward or other departments, whichever occurs first. The junior resident (principal investigator) will keep the observation on pain management, SAT and SBT trials conducted on patients, assessment and management of delirium, degree of mobilization and the family engagement regarding the patients in this group but no intervention will be applied upon. If any subject develops delirium during their hospital stay, the duration of the delirium, antipsychotic dosages required, and length of ICU stay will all be noted. However, all decisions regarding the management of the patient will be made completely by the treating physician and in accordance with conventional ICU care, with no active intervention being used on this control group.

In the next 1 month, the residents and staffs on duty will be trained on implementing the ABCDEF bundle in ICU patients on a weekly basis for 4 consecutive weeks before implementation of the ABCDEF bundle.